Technology areas: Biotechnology & Pharmaceuticals • Computing & Software
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
BENEVOLENTAI BIO LIMITED has 6 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners across 3 art units, showing that the portfolio requires coordination across several examination settings.
NEGIN, RUSSELL SCOTT is the busiest examiner, with 2 pending matters. That concentration identifies a useful point for docket review, while the remaining matters still require examiner-specific analysis across the other assignments.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NEGIN, RUSSELL SCOTT | 2 | 55.9% | +34.2% |
| ROSSI, VY BUI | 1 | 29.5% | +36.4% |
| NGUYEN, PETER | 1 | — | — |
| MORALES, PEDRO JESUS | 1 | 57.1% | +60.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18359093 | ENTITY SELECTION METRICS | ROSSI, VY BUI | — |
| 18326181 | METHOD FOR DETERMINING A MEASURE OF RELATIVE GENE EXPRESSION | NGUYEN, PETER | — |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | — |
| 17997448 | PATIENT STRATIFICATION USING LATENT VARIABLES | NEGIN, RUSSELL SCOTT | — |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18359093 | ENTITY SELECTION METRICS | ROSSI, VY BUI | — |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | — |
| 17997448 | PATIENT STRATIFICATION USING LATENT VARIABLES | NEGIN, RUSSELL SCOTT | — |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | — |
| Art Unit | Apps |
|---|---|
| 1685 | 2 |
| 1686 | 2 |
| 2124 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18359093 | ENTITY SELECTION METRICS | ROSSI, VY BUI | 1685 | §101§102§112DP | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18326181 | METHOD FOR DETERMINING A MEASURE OF RELATIVE GENE EXPRESSION | NGUYEN, PETER | 1685 | §101§102§103 | Non-Final OA | — | Pending | May 31, 2023 |
| 18007391 | GRAPH PATTERN INFERENCE | MORALES, PEDRO JESUS | 2124 | §101§103 | Final Rejection | — | Pending | Jan 30, 2023 |
| 17997448 | PATIENT STRATIFICATION USING LATENT VARIABLES | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Final Rejection | — | Pending | Oct 28, 2022 |
| 17772180 | DESIGNING A MOLECULE AND DETERMINING A ROUTE TO ITS SYNTHESIS | NEGIN, RUSSELL SCOTT | 1686 | §101§103 | Final Rejection | — | Pending | Apr 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBENEVOLENTAI BIO LIMITED has 5 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Russell Scott Negin has the most, with 2 of BENEVOLENTAI BIO LIMITED's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
